European Medicines Agency concludes on use of celecoxib in familial adenomatous polyposis

View source ↗

Summary

EMA concludes on the use of celecoxib for familial adenomatous polyposis (FAP), informing regulatory stance and potential labeling considerations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Adenomatous Polyposis

Drugs mentioned

• Celecoxib (Celecoxib)